Trial Profile

A Phase I/II, First-In-Human Trial of SRA141 for the Treatment of Advanced Colorectal Cancer

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 06 Mar 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Monzosertib (Primary)
Indications Colorectal cancer
Focus Adverse reactions; First in man
Sponsors Sierra Oncology

Most Recent Events

28 Feb 2019 According to a Sierra Oncology media release, the company is currently evaluating the optimal timing to commence this trial.
13 Nov 2018 According to a Sierra Oncology media release, the Investigational New Drug Application (IND) process for SRA141 with the FDA has been completed and the IND application for SRA141 has been accepted by the U.S. FDA.
10 Aug 2018 According to a Sierra Oncology media release, Upon dosing of the first patient in the first Phase 1 clinical trial of SRA141, a milestone payment of $4.0 million will be due to Carna Biosciences, Inc. (Carna), the licensor of this asset.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com